CNS-penetrant tubulin-binder (colchicine site)

oral agent in Ph. I for leiomyosarcoma

not a P-gp substrate, formerly BMI-1 inh.

Molecular Cancer Therapeutics

PTC Therapeutics, South Plainfield, US

The PTC Therapeutics oral, brain-penetrant tubulin-binding agent, PTC596, is in Ph. I clinical studies for advanced solid tumors (starting dose of 200 mg PO BIW). We recently highlighted encequidar, a P-gp…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks